drugset / Trial / NCT00447525

REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children

NCT00447525

Phase 3 Completed 760 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

Primary objective: To demonstrate the non inferiority between REVAXIS® and DT Polio® when given as a second booster to healthy 6 year-old children . Secondary objectives: * Additional immunogenicity assessments. * To describe the safety profile of a single dose of REVAXIS® or DT-Polio®

Timeline

Start
2007-02
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator DT-Polio® Vaccine Intramuscular
Subject REVAXIS® Vaccine Intramuscular